Low muscle mass in people with inoperable pancreatic cancer undergoing chemoradiotherapy, or CRT, was linked with more treatment-related toxicities and shorter overall survival in…
News
The U.S. Food and Drug Administration (FDA) has agreed to a priority review of a Chimerix application seeking accelerated approval of dordaviprone, its oral…
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Regeneron Pharmaceuticals seeking the approval of linvoseltamab to treat…
GYNECOLOGICAL CANCER
CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
The U.S. Food and Drug Administration (FDA) has granted fast-track status to CUSP06, Oncusp Therapeutics’ treatment candidate for platinum-resistant ovarian cancer. This designation…
A triple-combination therapy using tuspetinib, Aptose Biosciences‘ experimental oral therapy, is showing potential in treating adults with newly diagnosed acute myeloid leukemia (AML),…
PANCREATIC CANCER
PAC-MANN blood test shows high accuracy in ID’ing pancreatic cancer
A new blood test called PAC-MANN can detect the most common type of pancreatic cancer with high accuracy, according to a study led by…
An experimental immune-modulating therapy called KROS 101 was able to activate immune cells to kill glioma cells in laboratory experiments, according to new preclinical…
GYNECOLOGICAL CANCER
FDA gives RMAT status to Vigil immunotherapy for ovarian cancer
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Gradalis’ experimental immunotherapy platform Vigil (Gemogenovatucel-T) as…
A first patient with relapsed/refractory multiple myeloma (RRMM) treated with CT0590, Carsgen Therapeutics’ CAR T-cell therapy, showed a complete response to the…
Treatment with the cancer vaccine galinpepimut-S (GPS) is showing promise to potentially improve survival in people with acute myeloid leukemia (AML), a type of…
Recent Posts
- FDA to review glioma imaging agent, sets September decision date
- I’m taking up walking to combat the fog of ‘chemo brain’
- FDA OKs first-in-human trial of cell therapy for hard-to-treat AML
- First-of-its-kind solid tumor cell therapy prepares to debut in China
- Patients and caregivers can tap into the power of humor, too
